Vamikibart


Vamikibart is an investigational humanized monoclonal antibody developed by Genentech that targets interleukin-6, a pro-inflammatory cytokine.
It is being evaluated for the treatment of uveitic macular edema and diabetic macular edema, conditions characterized by retinal swelling due to inflammation or vascular leakage.
Vamikibart aims to provide a steroid-sparing treatment option by reducing intraocular inflammation and improving visual outcomes.

Mechanism of action

Vamikibart is a recombinant humanized IgG-based monoclonal antibody that specifically binds and inhibits IL-6, a key mediator of inflammation in ocular diseases like UME and DME. By blocking IL-6’s interaction with its receptor, vamikibart reduces inflammatory signaling pathways that contribute to retinal leakage and swelling, thereby improving best-corrected visual acuity and reducing macular edema. Administered via intravitreal injection, it delivers targeted therapy to the eye, minimizing systemic side effects.

Clinical development

Vamikibart is in advanced clinical trials for UME and DME, focusing on its efficacy, safety, and potential as a non-steroidal treatment.

Uveitic Macular Edema (UME)

  • DOVETAIL Study : This study assessed the safety, tolerability, and preliminary efficacy of intravitreal vamikibart in patients with non-infectious uveitis and concurrent macular edema. Patients received doses of 0.25 mg, 1 mg, or 2.5 mg, administered three times. Results showed rapid BCVA improvements and reduced retinal thickness. Approximately 25–33% of patients achieved ≥15-letter BCVA improvements, with no need for steroid co-treatment.
  • MEERKAT and SANDCAT Studies : These ongoing, global, randomized, double-masked, sham-controlled trials evaluate vamikibart’s efficacy and safety in UME. The primary outcome is the proportion of patients with ≥15-letter BCVA improvement from baseline at Week 16.

Diabetic Macular Edema (DME)

  • NCT05151744 Study : This multicenter, randomized, double-masked, active comparator-controlled trial investigates vamikibart in combination with ranibizumab versus ranibizumab alone in DME patients. It evaluates efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics.

Safety and adverse effects

Vamikibart has shown a favorable safety profile in the DOVETAIL Phase 1 trial, with no reported need for steroid co-treatment. Common adverse events associated with intravitreal injections, such as conjunctival haemorrhage, eye pain, and vitreous floaters, may occur, though specific adverse events for vamikibart are still being evaluated in ongoing Phase 3 trials.

Regulatory status

Vamikibart is an investigational drug and has not been approved for commercial use. It has received an orphan drug designation from the European Medicines Agency for the treatment of non-infectious uveitis.

History

Vamikibart was developed by Roche/Genentech to address unmet needs in ocular inflammatory and vascular diseases. The DOVETAIL Phase 1 trial, presented at the American Academy of Ophthalmology 2024 Meeting in Chicago, demonstrated its potential as a steroid-sparing therapy for UME. Its advancement to Phase 3 trials and Phase 2 trials for DME reflects growing interest in IL-6-targeted therapies for retinal disorders.